公开(公告)号：US20050142634A1

公开(公告)日：2005-06-30

申请号：US10473753

申请日：2002-04-03

申请人： Boris Cheskis ,  Elliott Nickbarg ,  Chi-Wai Wong

发明人： Boris Cheskis ,  Elliott Nickbarg ,  Chi-Wai Wong

IPC分类号： A01K67/027 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/74 ,  C07H21/04 ,  C07K14/72 ,  C12N1/18

CPC分类号： C07K16/18 ,  C07K14/4702 ,  G01N33/743 ,  G01N2333/70567 ,  G01N2333/723

摘要： A novel protein modulator of non-genomic activity of nuclear receptors (MNAR), which interacts with estrogen receptors alpha (ERα), estrogen receptor beta (ERβ), and other nuclear receptors, was discovered and characterized. An MNAR-ER complex, in vitro and in vivo, relates to nucleic acids, antisense, recombinant expression of nucleic acids, as well as host cells, compositions and assays that utilize the nucleic acids and protein of this invention.

摘要翻译： 发现并表征了与雌激素受体α（ERalpha），雌激素受体β（ERbeta）和其他核受体相互作用的核受体（MNAR）的非基因组活性的新型蛋白质调节剂。 在体外和体内的MNAR-ER复合物涉及核酸，核酸的反义重组表达，以及利用本发明的核酸和蛋白质的宿主细胞，组合物和测定法。

公开(公告)号：US07273707B2

公开(公告)日：2007-09-25

申请号：US10361270

申请日：2003-02-10

申请人： Jun Kuai ,  Joseph L. Wooters ,  Elliott Nickbarg ,  Yongchang Qiu ,  Lih-Ling Lin

发明人： Jun Kuai ,  Joseph L. Wooters ,  Elliott Nickbarg ,  Yongchang Qiu ,  Lih-Ling Lin

IPC分类号： G01N33/53 ,  C07K1/00

CPC分类号： G01N33/6863 ,  C07K14/7151 ,  G01N33/57492 ,  G01N2333/525 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2510/00

摘要： The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided.

摘要翻译： 本发明涉及包含激活或抑制LTbetaR信号传导的淋巴毒素-β受体（LTbetaR）调节剂的组合物和方法。 LTbetaR调节剂可用于治疗淋巴细胞介导的免疫疾病和癌症，更具体地，用于调节线粒体介导的细胞凋亡。 本发明涉及用作LTbetaR活化或抑制剂的LTbetaR复合蛋白的可溶形式。 本发明还涉及用于调节LTbetaR信号传导的功能的LTbetaR，其配体LIGHT和LTbeta1alpha2或其胞内结合配偶体的可溶性分子的用途。 提供了一种新的筛选方法，用于选择调节LTbetaR信号传导的可溶性受体，抗体和其他试剂。

公开(公告)号：US20070128210A1

公开(公告)日：2007-06-07

申请号：US11592128

申请日：2006-11-03

申请人： Stephen Olmsted ,  Robert Zagursky ,  Elliott Nickbarg ,  Laurie Winter

发明人： Stephen Olmsted ,  Robert Zagursky ,  Elliott Nickbarg ,  Laurie Winter

IPC分类号： C07K14/315 ,  A61K39/02 ,  C07H21/04 ,  C07K16/12 ,  C12N15/74 ,  C12N1/21

CPC分类号： C07K14/315

摘要： β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci in a biological sample.

公开(公告)号：US20080248460A1

公开(公告)日：2008-10-09

申请号：US11825385

申请日：2007-07-06

申请人： Jun Kuai ,  Joseph L. Wooters ,  Elliott Nickbarg ,  Yongchang Qiu ,  Lih-Ling Lin

发明人： Jun Kuai ,  Joseph L. Wooters ,  Elliott Nickbarg ,  Yongchang Qiu ,  Lih-Ling Lin

IPC分类号： C12Q1/70 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/573

CPC分类号： G01N33/6863 ,  C07K14/7151 ,  G01N33/57492 ,  G01N2333/525 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2510/00

摘要： The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided.

摘要翻译： 本发明涉及包含激活或抑制LTbetaR信号传导的淋巴毒素-β受体（LTbetaR）调节剂的组合物和方法。 LTbetaR调节剂可用于治疗淋巴细胞介导的免疫疾病和癌症，更具体地，用于调节线粒体介导的细胞凋亡。 本发明涉及用作LTbetaR活化或抑制剂的LTbetaR复合蛋白的可溶形式。 本发明还涉及用于调节LTbetaR信号传导的功能的LTbetaR，其配体LIGHT和LTbeta1alpha2或其胞内结合配偶体的可溶性分子的用途。 提供了一种新的筛选方法，用于选择调节LTbetaR信号传导的可溶性受体，抗体和其他试剂。

公开(公告)号：US20070128229A1

公开(公告)日：2007-06-07

申请号：US11592200

申请日：2006-11-03

申请人： Stephen Olmsted ,  Robert Zagursky ,  Elliott Nickbarg ,  Laurie Winter

发明人： Stephen Olmsted ,  Robert Zagursky ,  Elliott Nickbarg ,  Laurie Winter

IPC分类号： A61K39/09 ,  C07H21/04 ,  C07K14/315 ,  C12N1/21

CPC分类号： C07K14/315 ,  A61K39/00 ,  A61K39/09

摘要： β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci in a biological sample.

摘要翻译： 描述了β-溶血性链球菌多核苷酸，多肽，特别是化脓性链球菌多肽和多核苷酸，以及这些多肽的抗体。 本发明的多核苷酸，多肽和抗体可配制成用作免疫原性组合物。 还公开了用于免疫抗原和减少β-溶血性链球菌感染以及用于检测生物样品中的β-溶血性链球菌的方法。

公开(公告)号：US20070128211A1

公开(公告)日：2007-06-07

申请号：US11592153

申请日：2006-11-03

申请人： Stephen Olmsted ,  Robert Zagursky ,  Elliott Nickbarg ,  Laurie Winter

发明人： Stephen Olmsted ,  Robert Zagursky ,  Elliott Nickbarg ,  Laurie Winter

IPC分类号： A61K39/02 ,  C07H21/04 ,  C12P21/06 ,  C07K14/315 ,  C07K16/12 ,  C12N15/74

CPC分类号： C07K14/315

摘要： β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci in a biological sample.

公开(公告)号：US20060078944A1

公开(公告)日：2006-04-13

申请号：US10523328

申请日：2003-08-01

申请人： Jun Kuai ,  Lih-Ling Lin ,  Joseph Wooters ,  Elliott Nickbarg

发明人： Jun Kuai ,  Lih-Ling Lin ,  Joseph Wooters ,  Elliott Nickbarg

IPC分类号： G01N33/53 ,  C12P21/02 ,  C12N9/12 ,  C07K14/535 ,  C07K14/715

CPC分类号： C40B30/04 ,  A61K38/00 ,  C07K14/525 ,  C07K14/7151 ,  C07K19/00 ,  C07K2319/00

摘要： The present invention relates to, among other embodiments, protein complexes which include tumor necrosis factor alpha (TNF-α) and/or tumor necrosis factor alpha receptor (TNFR). Preferably, the complexes comprise at least one polypeptide selected from the group consisting of: NF-κB activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. The present invention further provides assays of identifying a compound for modulating the stability and activity of the complex. Also provided are methods of modulating apoptosis and inflammation, as well as treating TNF-α related diseases.

摘要翻译： 本发明尤其涉及包括肿瘤坏死因子α（TNF-α）和/或肿瘤坏死因子α受体（TNFR）的蛋白质复合物。 优选地，复合物包含至少一种选自以下的多肽：NF-κB激活激酶（NAK），RasGAP3，TRCP1和TRCP2。 本发明进一步提供鉴定用于调节复合物的稳定性和活性的化合物的测定。 还提供了调节凋亡和炎症以及治疗TNF-α相关疾病的方法。